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cytometry and ADP-induced platelet aggregation (PAG), measured by light trans-
mission aggregometry].
Results: All the subjects were dichotomized according to PRI medians (normal-re-
sponders: PRI<41.85%, n¼45 and low-responders: PRI>41.85%, n¼45) and PAG
medians (normal-responders: PAG<65.5%, n¼49 and low-responders: PAG>65.5%,
n¼41). No signiﬁcant differences of demographic data were found between normal-
and low-responders determined by the two methods. To further explore the potential
clinical characteristics associated with the discrepancy of VASP phosphorylation and
PAG in evaluating platelet reactivity, patients who were normal-responders to both
methods, or who were low-responders to both methods, were deﬁned as “concor-
dance” group (n¼60). Otherwise, the rest patients were deﬁned as “discrepancy
group” (n¼30). Stepwise binary logistic regression analysis revealed that among
factors that potentially inﬂuence the consistency of the two methods, smoking was the
only independent predictor associated with the discrepancy of the two methods (OR
3.333, 95% CI 1.120 to 9.917, P¼0.030). After adjusted by the traditional factors
(age, gender, hypertension and diabetes) that may inﬂuence the responsiveness of
platelets to clopidogrel, smoking remains statistically predict the discrepancy between
these two methods in evaluating platelet reactivity (OR 4.399, 95% CI 1.105 to
17.522, P¼0.036).
Conclusions: The present study shows that smoking is an independent factor that
inﬂuences the consistancy of VASP phosphorylation and ADP-induced PAG in
evaluating high on-clopidogrel platelet reactivity in patients with STEMI.
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The platelet receptor P2Y12 gene polymorphisms and thrombelastography could
predict the risk of bleeding events in clopidogrel-treated Chinese patients after
percutaneous coronary intervention
Zhang Jiahui, Tang Xiaofang, Wang Jing, Yao Yi, Gao Runlin, Gao Zhan, Wu Yuan,
Chen Jue, Meng Xianmin, Yuan Jinqing
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Objectives: Polymorphisms in the platelet receptor P2Y12 gene have been suggested
to inﬂuence the pharmacodynamics of clopidogrel and prognosis of patients treated
with clopidogrel. The effect of P2Y12 polymorphisms and the prognostic utility of
thrombelastography (TEG) on bleeding events of clopidogrel treatment have not yet
been reported in Chinese patients after percutaneous coronary intervention (PCI). This
study sought to investigate the impact of P2Y12 polymorphisms and the predictive
value of TEG on the risk of bleeding in clopidogrel-treated Chinese patients after PCI.
Methods: Between January 2011 and June 2012, 504 consecutive patients with acute
coronary syndromes (ACS) who received coronary angiography or an uneventful PCI
and were exposed to clopidogrel treatment for 12 months, were enrolled in the single-
center registry. 18 tag single nucleotide polymorphisms (SNPs) selected from P2Y12
gene and the gain of function CYP2C19*17 allele were detected by the ligase
detection reaction. The antiplatelet effect of clopidogrel was assessed by TEG. The
primary clinical safety end point was the incidence of major bleeding deﬁned ac-
cording to the Bleeding Academic Research Consortium (BARC) criteria, including
type 3 and 5 in the analysis. The primary clinical efﬁcacy end point was a composite
of cardiovascular death, non-fatal myocardial infarction, unplanned target vessel
revascularization, and stent thrombosis. The follow-up period was 12 months.
Results: Major bleeding events occurred in 47 patients (9.3%) according to BARC
criteria, including 12 patients or 2.4% with BARC type 3b bleeding, 35 patients or
6.9% with BARC type 3a bleeding. By receiver operating characteristic curve anal-
ysis, the TEG results of ADP inhibition >80.7% had a predictive value of BARC type
3 bleeding with an area under the curve¼ 0.556 (95%CI 0.511-0.6, p¼0.045).
Binary logistic regression analysis identiﬁed ADP inhibition >80.7% (OR: 2.637,
95%CI: 1.268-5.483, p¼0.009), and two tag SNPs rs6785930 (OR: 2.305, 95%CI:
1.180-4.503, p¼0.015), rs6809699 (OR: 3.227, 95%CI: 1.587-6.558, p¼0.001)) as
signiﬁcant independent predictors of BARC type 3 bleeding in the context of gain of
function CYP2C19*17 allele. A total of 34 ischemic events occurred. However, no
signiﬁcant inﬂuence of tag SNPs of P2Y12 on the occurrence of ischemic events was
found. TEG did not predict ischemic events, either.
Conclusions: In our study population, the P2Y12 genetic locus harbors SNPs that
could have inﬂuence on bleeding events after PCI, and the ADP inhibition of TEG had
a predictive value of bleedings.
GW25-e5372
CORRELATION OF NLRP3 WITH PROGNOSIS IN ACUTE CORONARY
SYNDROME
Qu Peng
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Objectives: To assess whether NLRP3 concentration was related to atherosclerotic
severity and any speciﬁc features of coronary lesions on angiographic assessment and
if NLRP3 concentration has any prognostic value in acute coronary syndrome (ACS)
patients.
Methods: In our study we examined one hundred and twenty three (123) subjects
including 30 controls (C¼30) and 93 Acute coronary Syndrome (ACS¼93) patients.
We evaluated the association of baseline NLRP3 level with clinical presentation,
angiographic characteristics, SYNTAX score, Clinical SYNTAX score (CSS) and
Gensini score. Follow up for major adverse cardiac events (MACE) was carried out atJACC Vol 64/16/Suppl C j October 16–19, 2014 j GW-ICC Abstracts/C6 months and Kaplan-Meier curves were constructed. Prognostic values of NLRP3,
GRACE score and TIMI score were determined by receiver operating characteristic
(ROC) curves.
Results: NLRP3 was found to be elevated in ACS patients (P<0.05). There was
positive correlation between NLRP3 and SYNTAX score, Clinical SYNTAX score
and Gensini score. P value was found to be 0.01 in all cases. NLRP3 was also
associated with severity of coronary disease based on number of vessels (P<0.05)
involved and the number of lesions (P<0.05) present and also on the presence or
absence of bifurcation lesions (P¼0.05). The 6 months mortality was 1.07% (1 pa-
tient), myocardial infarction 2.15% (2 patients) and unstable angina 3.22% (3 pa-
tients), target vessel revascularization was 3.22% (3 patients) and cardiac failure was
4.3% (4 patients). Receiver operating characteristic (ROC) curves of NLRP3 showed
good predictive value for MACE.
Conclusions: There are no previous studies related to correlation of NLRP3 levels and
severity of atherosclerosis. Our study showed positive correlation between NLRP3
concentration and SYNTAX score, CLINICAL SYNTAX score, GENSINI score,
Grace Score and TIMI score. Further studies are required to test the utilization of
NLRP3 in risk assessment and in selecting appropriate therapies for patients in low
and high risk groups as well as its utilization in decision making regarding the choice
of revascularization therapy.
GW25-e1169
Effect of different dose of rosuvastatin on the levels of serum adiponectin, vWF
and endothelial function in patients with acute coronary syndrome
Zhang Zhu-Lin, Zhang Li-Zhen, Ma Xiu-Rui, Lan Wen-Yan
Shanxi Cardiovascular Hospital
Objectives: To observe and compare the effect of different dose of rosuvastatin on the
levels of serum adiponectin (APN), von Willebrand factor (vWF) and endothelial
function in patients with acute coronary syndrome (ACS).
Methods: 120 patients with acute coronary syndrome were randomly assigned to
receive 10 mg/day or 20 mg /day of rosuvastatin. The levels of serum lipids, adipo-
nectin (APN), von Willebrand factor (vWF) and dilation of the brachial artery were
assessed before the therapy, 4 weeks and 8 weeks after the therapy.
Results: All the levels of total cholesterol, low-density lipoprotein cholesterol,
triglycerides were signiﬁcantly decreased from baseline values in Rosuvastatin
10 mg/d and 20 mg/d groups, and the levels of high-density lipoprotein cholesterol
increased. After treatment, the level of APN was increased, brachial artery ﬂow-
mediated endothelium-depended dilation were improved; while the level of vWF was
decreased. These effects were more signiﬁcant with rosuvastatin for 8 weeks than
4 weeks; but there was no difference between 10 mg/d and 20 mg/d.
Conclusions: Treatment with rosuvastatin 10 mg/d and 20 mg/d could improve
abnormal serum lipids and endothelial function, increase APN, decrease vWF. The
effect was greater with rosuvastatin for 20 mg/d than 10 mg/d and 8 weeks than
4 weeks.
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Genetic polymorphisms of CYP2C19*2 and ABCB1 C3435T affect the
pharmacokinetics and pharmacodynamics response to clopidogrel in patients
with acute coronary syndrome in the Chinese Han population
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Objectives: Clopidogrel is an inhibitor of platelet ADP P2Y12 receptors and plays
an important role in the prevention of stent thrombosis. Despite certain clinical
beneﬁt using this drug in patients undergoing percutaneous coronary intervention
(PCI), some patients do not attain adequate antiplatelet effects. Several studies report
that the genetic variation in CYP2C19 and ABCB1 is associated with an impaired
response to clopidogrel. This study was designed to investigate the genetic variants
of ABCB1, CYP2C9*2, CYP2C19*3, CYP3A4, CYP3A5, P2RY12 and P2Y1 on
exposure to clopidogrel (CLP), its active (clopi-H4) and inactive (CLPM) metabo-
lite, and platelet response to clopidogrel in Chinese Han population with acute
coronary syndrome.
Methods: The degree of inhibition of platelets was assessed using the light trans-
mittance aggregometry (LTA). Plasma concentrations of CLP, clopi-H4 and CLPM
were measured by HPLC-MS-MS method in 401 consecutive patients. Patients were
either on 75 mg clopidogrel-maintenance dose or received a 300 mg clopidogrel-
loading dose.
Results: In both the treatment groups, carriage of CYP2C19*2 and ABCB1 C3435T
was associated with lower exposure to clopi-H4 (P< 0.05) and thus decreased platelet
inhibition (P< 0.05), There was no signiﬁcant association between variant allele
PON1 and clopi-H4 formation or antiplatelet response to clopi-H4 in both groups (P>
0.05). CYP2C19*2 is a determinant for the formation of the active metabolite of
clopidogrel and its antiplatelet effects. Meanwhile, ABCB1 C3435T also plays an
important role in intestinal absorption of clopidogrel, which will further affect the
exposure to clopi-H4.
Conclusions: In both the treatment groups, carriage of CYP2C19*2 and ABCB1
C3435T was associated with lower exposure to clopi-H4 (P< 0.05) and thus decreased
platelet inhibition (P< 0.05), There was no signiﬁcant association between variant
allele PON1 and clopi-H4 formation or antiplatelet response to clopi-H4 in both
groups (P> 0.05). CYP2C19*2 is a determinant for the formation of the activeardiovascular Disease Clinical Research C127
metabolite of clopidogrel and its antiplatelet effects. Meanwhile, ABCB1 C3435T also
plays an important role in intestinal absorption of clopidogrel, which will further affect
the exposure to clopi-H4.
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Impact of obesity on long-term outcomes in patients with acute coronary
syndrome and without diabetes
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Objectives: Obesity is associated with an increased cardiovascular events in the
general population. However, recent studies have shown a paradoxic relation between
obesity and adverse outcomes in patients with type 2 diabetes, coronary artery disease,
heart failure, or hypertension. However, whether this phenomenon exists in patients
with acute coronary syndrome (ACS) but without diabetes is not known. The aim of
the study was to assess the impact of obesity on adverse outcomes in patients with
acute coronary syndrome (ACS) but without diabetes.
Methods: A total of 571 patients with ACS but without diabetes (72.5% was men,
mean age was 59.9  11.2 years) were included in a retrospective study, and with at
least 3 years’ follow-up. The endpoint events were major adverse cardiovascular
events (MACE), which included cardiac death, non-fatal myocardial infarction, and
rehospitalization with unstable angina. The primary outcomes were cardiac death and
non-fatal myocardial infarction. Patients were classiﬁed into 3 groups according to
baseline body mass index (BMI): less than 24 kg/m2 (normal weight), 24 to 28 kg/m2
(overweight), and 28 kg/m2 or more (obese).
Results: The incidence of long-term MACE was 33.6% and decreased with the levels
of BMI (the incidences of MACE were 37.9%, 34.1%, and 25.2%, respectively,
P trend¼0.031). Obese patients had a lower risk of MACE than their normal weight
counterparts (hazard ratio (HR) ¼0.58; 95% conﬁdence interval (CI), 0.37-0.91;
P¼0.016). After multivariable adjustment, the lower risk of MACE in obese patients
remained signiﬁcant (HR¼0.60; 95% CI, 0.39-0.94; P¼0.027). The overweight pa-
tients also had a lower risk of MACE than the normal weight patients in the single and
the multiple variables Cox models, but the differences were not signiﬁcant (the
P values were 0.271 and 0.272 in the single and multiple variables models, respec-
tively). Furthermore, the risks of the primary outcomes also decreased with BMI levels
in the single and multiple variables models, but all of the differences were not sta-
tistically signiﬁcant (P>0.05 for all).
Conclusions: In a population with ACS but without diabetes, obese patients had a
decreased risk of major adverse cardiovascular events compared with their normal
weight counterparts. In concordance with data in patients with diabetes, coronary
artery disease, hypertension, or heart failure, our ﬁndings further suggest a protective
effect of obesity on long-term outcomes in patients with ACS but without diabetes.
Furthermore, multi-center and large-scale prospective study are needed to evaluate the
ﬁndings.
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Growth differentiation factor 15 is an early predictor of heart failure in STEMI
patients
Xu Xinye, Wei Gao
Department of Cardiovascular Disease, Peking University Third Hospital
Objectives: To measure the concentration of GDF-15 in patients with STEMI and to
evaluate its potential to predict heart failure in this group of patients.
Methods: Fifty nine STEMI patients who were admitted to the hospital within 6 hours
of symptom onset were enrolled in the study. Biomarkers were measured both
immediately at the time of STEMI diagnosis and 24 hours later. Killip classiﬁcation
was evaluated 24 hours after admission.
Results: GDF-15 levels were high at the time of admission and were positively
correlated with both Killip classiﬁcation and pulmonary artery systolic pressure
(PASP). Brain natriuretic peptide (BNP) signiﬁcantly increased 24 hours after
admission and also positively correlated with Killip classiﬁcation and PASP. How-
ever, at the time of admission, there was no signiﬁcant correlation. One-way ANOVA
revealed signiﬁcant differences in GDF-15 concentrations among the different Killip
classes. Based on the receiver-operating-characteristic (ROC) curve, we determined
that a value of 716.6 pg/mL corresponded to a Killip classiﬁcation greater than Class
II; a value of 1021.1 pg/mL corresponded to a classiﬁcation higher than Class III.
Other biomarkers that were assessed in the study included TnT, IL-6, IL-8, IL-10, and
MCP-1; none of these markers correlated with either PASP or Killip class.
Conclusions: In patients with STEMI, GDF-15 is increased prior to BNP. GDF-15
may predict risk of congestive heart failure following STEMI.
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Obstructive Sleep Apnea and Gensini Score in Suspected Coronary Artery
Disease Patients
Peng Long, Jinlai Liu
the Third Afﬁliated Hospital, Sun Yat-sen UniversityC128 JACC Vol 64/16/Suppl C j October 16–1Objectives: The relationship between obstructive sleep apnea (OSA) and severity of
coronary artery disease (CAD) remains unclear. The present study aimed to determine
the association between OSA severity and Gensini score detected by 320-slice cor-
onary CTA in suspected CAD patients.
Methods: A total of 285 consecutive men (age: 60.3 9.8 years; BMI: 27.5  5.8 kg/
m2) who received polysomnography and 320-slice coronary CTA for suspected CAD
were included. Patients with prior revascularization were excluded. Suspected CAD
depended on angina-like symptoms, elevated cardiovascular risk, abnormal echocar-
diogram, positive stress ECG test and/or myocardial perfusion scintigraphies. OSA
was diagnosed according to polysomnography when the apnea-hypopnea index (AHI)
is greater than 5. Gensini scores, a method to evaluate the severity of coronary artery
disease, were gathered from 320-slice coronary CTA using the AHA 15-segment
model of coronary trees. The volunteers were divided to three groups according to
AHI: no-OSA group (AHI5), mild-OSA group (5<AHI<30) and severe-OSA group
(AHI30). Gensini scores were compared among groups using two-way ANOVA.
Spearman coefﬁcient was calculated to explore the correlation between AHI and
Gensini scores. p<0.01 was considered statistically signiﬁcant.
Results: Based on AHI, 153 patients were categorized into no-OSA group, 84 into
mild-OSA group and 48 into severe-OSA group. There were no statistical differences
among three groups in BMI, blood pressure, serum lipid level and blood glucose level.
Compared with no-OSA group, Gensini scores in mild-OSA (34.7217.47 vs
20.9613.27, p<0.01) and severe-OSA group (55.3420.57 vs 20.9613.27
p<0.01) were signiﬁcantly higher. Moreover, Gensini score in mild-OSA group was
signiﬁcantly lower than severe-OSA group (34.7217.47 vs 55.3420.57, p<0.01).
Spearman coefﬁcient indicated that the AHI of OAS positively correlated with Gensini
scores (r¼0.578, p<0.01).
Conclusions: Our study found an obvious correlation between OSA severity and
Gensini score in suspected CAD patients. OSA severity should be an assessment of
CAD risk.
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Thrombus aspiration improves all-cause death in long term follow-up in patients
undergoing percutaneous coronary intervention for ST-segment elevation
myocardial infarction: a meta-analysis of randomized trials
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Objectives: Clinical trials produced conﬂicting results of routine intracoronary
thrombus aspiration (TA) before primary percutaneous coronary intervention (PCI) in
ST-segment elevation myocardial infarction (STEMI) patients. This study was to
perform an updated meta-analysis of randomized trials to evaluate all-cause death
events, other clinical outcomes [major adverse cardiac event (MACE), re-myocardial
infarction (Re-MI), stent thrombosis (ST), target-vessel revascularization (TVR),
target-lesion revascularization (TLR) ] and the makers of myocardial reperfusion
between TA prior to PCI (TA+PCI) compared with PCI only in STEMI patients.
Methods: The primary sources were the electronic databases of PubMed, Embase,
and the Cochrane Library from January 1990 to November 2013. Randomized clinical
trials comparing sildenaﬁl to placebo, in heart failure patients, reporting at least one
outcome of interest were included. Data were extracted regarding the characteristics
and clinical outcomes, and combined using a ﬁxed or random effect meta-analysis.
Results: A total of 25 randomized trials with 12940 patients were included. TA+PCI
A total of 25 randomized trials with 12940 patients were included. TA+PCI was
associated with signiﬁcant beneﬁts in terms of all-cause death in 6 months follow-up
(P ¼ 0.03) but not in 30 days (P ¼ 0.20). As for other clinical outcomes in 30 days
follow-up, TA+PCI was only associated with a trend of lower Re-MI rate, and in 6
months follow-up, TA+PCI had signiﬁcant lower rates of MACE, Re-MI and TLR as
compared with PCI only. Besides, TA+PCI were associated with signiﬁcantly
improved markers of myocardial reperfusion.
Conclusions: TA+PCI was associated with signiﬁcant beneﬁts in terms of all-cause
death, MACE, Re-MI and TLR in 6 months follow-up but not in 30 days follow-up,
with signiﬁcantly improved markers of myocardial reperfusion. Thus, TA is recom-
mended for routine use among STEMI patients undergoing PCI for long term
consideration.
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Resting Heart Rate Associates with 1-Year Risk of Major Adverse
Cardiovascular Events in Patients with Acute Coronary Syndrome after
Percutaneous Coronary Intervention
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Objectives: The study was to access the association between resting heart rate (RHR)
and 1-year risk of major adverse cardiovascular events (MACE) in acute coronary
syndrome (ACS) patients after percutaneous coronary intervention (PCI).
Methods: A total of 808 participants with ACS after successful PCI were assigned to
the conventional treatment. MACE was deﬁned as a composite of cardiac death,
nonfatal recurrent myocardial infarction (MI), ischemic-driven revascularization, and9, 2014 j GW-ICC Abstracts/Cardiovascular Disease Clinical Research
